MX336675B - Cribado para compuestos anticancerigenos utilizando actividad de netrina-1. - Google Patents

Cribado para compuestos anticancerigenos utilizando actividad de netrina-1.

Info

Publication number
MX336675B
MX336675B MX2008011067A MX2008011067A MX336675B MX 336675 B MX336675 B MX 336675B MX 2008011067 A MX2008011067 A MX 2008011067A MX 2008011067 A MX2008011067 A MX 2008011067A MX 336675 B MX336675 B MX 336675B
Authority
MX
Mexico
Prior art keywords
netrin
cancer
screening
activity
compounds
Prior art date
Application number
MX2008011067A
Other languages
English (en)
Other versions
MX2008011067A (es
Inventor
Patrick Mehlen
Agnès Bernet
Julien Fitamant
Original Assignee
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient filed Critical Centre Nat Rech Scient
Publication of MX2008011067A publication Critical patent/MX2008011067A/es
Publication of MX336675B publication Critical patent/MX336675B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a un método in vitro para el cribado de compuestos anticancerígenos en base en la capacidad de estos compuestos de interactuar con el receptor de netrina-1 y/o para inhibir la dimerización del dominio intracelular del receptor de netrina-1 expresado en células tumorales; la invención también se relaciona con un método para predecir la presencia de cáncer metastásico o agresivo o para determinar la eficiencia de un tratamiento anticanceroso en base en la medición del nivel de expresión de netrina-1; la invención comprende adicionalmente equipos y compuestos como un medicamento para el tratamiento de cáncer tal como cáncer de mama metastásico, relacionado con la sobreexpresión de netrina-1 por las células tumorales.
MX2008011067A 2006-02-28 2007-02-28 Cribado para compuestos anticancerigenos utilizando actividad de netrina-1. MX336675B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77692606P 2006-02-28 2006-02-28
PCT/EP2007/051920 WO2007099133A1 (en) 2006-02-28 2007-02-28 Screening for anti-cancer compounds using netrin-1 activity

Publications (2)

Publication Number Publication Date
MX2008011067A MX2008011067A (es) 2008-11-25
MX336675B true MX336675B (es) 2016-01-27

Family

ID=38051332

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008011067A MX336675B (es) 2006-02-28 2007-02-28 Cribado para compuestos anticancerigenos utilizando actividad de netrina-1.

Country Status (21)

Country Link
US (3) US20090226458A1 (es)
EP (1) EP1989546B1 (es)
JP (1) JP5602368B2 (es)
KR (2) KR101587932B1 (es)
CN (1) CN101389958B (es)
AU (1) AU2007220515B2 (es)
BR (1) BRPI0707040B8 (es)
CA (1) CA2638974C (es)
CY (1) CY1118325T1 (es)
DK (1) DK1989546T3 (es)
ES (1) ES2601352T3 (es)
HU (1) HUE030738T2 (es)
IL (1) IL193580A (es)
LT (1) LT1989546T (es)
MX (1) MX336675B (es)
PL (1) PL1989546T3 (es)
PT (1) PT1989546T (es)
SG (1) SG172645A1 (es)
SI (1) SI1989546T1 (es)
WO (1) WO2007099133A1 (es)
ZA (1) ZA200806913B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009141440A1 (en) * 2008-05-21 2009-11-26 Centre National De La Recherche Scientifique (Cnrs) Netrin-1 overexpression as a biological marker and a survival factor for aggressive neuroblastoma
US20110229485A1 (en) * 2008-05-21 2011-09-22 Centre National De La Recherche Scientfique (Cnrs) Inhibition of the nt-3:trkc bound and its application to the treatment of cancer such as neuroblastoma
EP2208738A1 (en) * 2009-01-09 2010-07-21 Centre National pour la Recherche Scientifique (CNRS) Method for the selection of endothelial cells death inducers via netrin-1 and its applications
WO2010090834A2 (en) * 2009-01-20 2010-08-12 The Penn State Research Foundation Netrin-1 as a biomarker of injury and disease
EP2267153A1 (en) * 2009-05-26 2010-12-29 Université Claude Bernard Lyon 1 Identification of netrin-1 receptor unc5c gene mutation in solid cancers
US9050298B2 (en) 2010-05-28 2015-06-09 The Regents Of The University Of California Method of treating ischemia/reperfusion injuries to a heart with netrin-1
KR20140004632A (ko) 2010-08-26 2014-01-13 에프. 호프만-라 로슈 아게 DCC의 제 5 피브로넥틴 유형 III 도메인의 재조합 Fc-융합 단백질
JP2015504510A (ja) * 2011-11-04 2015-02-12 インヴィヴィス，エスエーエス 抗エストロゲン剤の効果予測バイオマーカーのアッセイ
EP2708241A1 (en) 2012-09-12 2014-03-19 Netris Pharma Recombinant Fc-fusion protein of the two Immunoglobulin domains of UNC5
EP2708231A1 (en) 2012-09-12 2014-03-19 Netris Pharma Combined treatment with netrin-1 interfering drug and chemotherapeutic drug
EP2893939A1 (en) * 2014-01-10 2015-07-15 Netris Pharma Anti-netrin-1 antibody
CN105031611B (zh) * 2015-06-18 2018-02-09 中国医学科学院基础医学研究所 netrin‑1蛋白在制备用于肿瘤治疗的药物中的用途
TW201720459A (zh) 2015-11-02 2017-06-16 妮翠斯製藥公司 Ntn1中和劑與抑制後生控制之藥物之組合治療
US10379534B2 (en) * 2016-01-28 2019-08-13 Qualcomm Incorporated Drone flight control
CN107011444B (zh) * 2016-01-28 2021-11-16 中国科学院脑科学与智能技术卓越创新中心 一种筛选hERG钾离子通道激动剂和毒性检测方法
CN105925578A (zh) * 2016-05-30 2016-09-07 东北师范大学 靶向沉默Neogenin的shRNA
JP7211952B2 (ja) 2017-01-05 2023-01-24 ネトリス ファーマ ネトリン－１干渉薬及び免疫チェックポイント阻害薬による併用治療
US20230204565A1 (en) * 2020-01-02 2023-06-29 The Regents Of The University Of California Methods for Culturing Cancer Cells and for Inhibiting Invasion of Cancer
CN112812167B (zh) * 2021-01-06 2023-04-11 东北师范大学 一种促进细胞存活的Netrin-1模拟肽、Netrin-1截短多肽及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3611194A1 (de) * 1986-04-04 1987-10-08 Bayer Ag Cancerostatisches mittel
US5565331A (en) 1993-11-12 1996-10-15 The Regents Of The University Of California Nucleic acids encoding neural axon outgrowth modulators
AU704341B2 (en) 1995-06-30 1999-04-22 Genzyme Corporation Novel human chromosome 16 genes, compositions, methods of making and using same
US6030806A (en) 1995-06-30 2000-02-29 Landes; Gregory M. Human chromosome 16 genes, compositions, methods of making and using same
US5824775A (en) 1996-04-19 1998-10-20 The Regents Of The University Of California Human netrin-1
JPH11335398A (ja) 1998-05-22 1999-12-07 Hoechst Marion Roussel Kk 新規な骨誘導活性を有する単量体蛋白質およびそれらからなる軟骨・骨疾患の予防および治療薬
US5939271A (en) 1997-02-19 1999-08-17 The Regents Of The University Of California Netrin receptor
US20060025335A1 (en) * 2004-01-30 2006-02-02 Kinane Thomas B Netrin compositions and methods of using the same
AU2005250185A1 (en) * 2004-06-04 2005-12-15 Laboratoires Serono Sa Splice variant of UNC5H2
WO2006019904A1 (en) * 2004-07-14 2006-02-23 University Of Utha Research Foundation Netrin-related compositions and uses
CA2587921A1 (fr) 2004-11-22 2006-05-26 Centre National De La Recherche Scientifique Netrine 4 mutee, ses fragments et leur utilisation comme medicaments
CA2489780A1 (en) 2005-01-12 2006-07-12 Inserm Methods for preventing or treating a condition or a disease associated with angiogenesis
US20060153840A1 (en) * 2005-01-12 2006-07-13 Anne Eichmann Methods for preventing or treating a condition or a disease associated with angiogenesis
JP4677376B2 (ja) 2006-07-07 2011-04-27 キヤノン株式会社 画像処理装置、画像処理方法、画像処理プログラム及び記憶媒体
WO2009141440A1 (en) * 2008-05-21 2009-11-26 Centre National De La Recherche Scientifique (Cnrs) Netrin-1 overexpression as a biological marker and a survival factor for aggressive neuroblastoma

Also Published As

Publication number Publication date
BRPI0707040B1 (pt) 2021-11-23
KR20080113368A (ko) 2008-12-30
KR101587932B1 (ko) 2016-01-22
IL193580A0 (en) 2009-02-11
WO2007099133A1 (en) 2007-09-07
BRPI0707040A2 (pt) 2011-04-12
US20150004159A1 (en) 2015-01-01
AU2007220515B2 (en) 2013-02-14
IL193580A (en) 2013-08-29
CY1118325T1 (el) 2017-06-28
JP2009528525A (ja) 2009-08-06
AU2007220515A1 (en) 2007-09-07
US20180291106A1 (en) 2018-10-11
DK1989546T3 (en) 2016-11-21
LT1989546T (lt) 2016-12-27
ZA200806913B (en) 2009-08-26
MX2008011067A (es) 2008-11-25
BRPI0707040B8 (pt) 2022-03-08
CN101389958A (zh) 2009-03-18
SI1989546T1 (sl) 2016-12-30
CN101389958B (zh) 2014-04-09
CA2638974A1 (en) 2007-09-07
JP5602368B2 (ja) 2014-10-08
HUE030738T2 (en) 2017-05-29
CA2638974C (en) 2018-07-24
US11203641B2 (en) 2021-12-21
SG172645A1 (en) 2011-07-28
EP1989546B1 (en) 2016-08-31
ES2601352T3 (es) 2017-02-14
KR20140129391A (ko) 2014-11-06
US20090226458A1 (en) 2009-09-10
EP1989546A1 (en) 2008-11-12
PT1989546T (pt) 2016-12-05
PL1989546T3 (pl) 2017-03-31

Similar Documents

Publication Publication Date Title
MX336675B (es) Cribado para compuestos anticancerigenos utilizando actividad de netrina-1.
NZ607282A (en) Method for using gene expression to determine prognosis of prostate cancer
WO2008104543A3 (en) Method for predicting the occurrence of metastasis in breast cancer patients
TR201903981T4 (tr) Kanser tedavisi için bileşikler.
WO2011057034A3 (en) Catenae: serosal cancer stem cells
AU2010220421A8 (en) Antibodies against a proliferating inducing ligand (APRIL)
MX2010005960A (es) Biomarcadores de braf.
HK1108284A1 (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
WO2005084109A3 (en) Cancer specific gene mh15
MX347515B (es) Agentes que se unen al receptor encrespado y usos de los mismos.
MX2010008496A (es) Metodo para la determinacion de sensibilidad a agente anticancerigeno.
MX2013014153A (es) Biomarcadores paa terapia de inhibidor de hedgehog.
EA200970108A1 (ru) Композиции и способы для ингибирования роста smad4-дефицитных форм рака
HK1145342A1 (en) Prognosis prediction for melanoma cancer
WO2007061922A3 (en) Methods to predict and prevent resistance to taxoid compounds
WO2009019368A3 (fr) Procede de dosage de la liver fatty acid-binding protein, de l'ace et du ca19-9 pour le diagnostic in vitro du cancer colorectal
WO2012093821A3 (ko) 초기유방암의 예후 예측용 유전자 및 이를 이용한 초기유방암의 예후예측 방법
GEP20125647B (en) Kinesin inhibitors as cancer therapeutics
WO2013025952A3 (en) Methods and compositions for the treatment and diagnosis of breast cancer
EA201390744A1 (ru) Антикластериновые антитела и антигенсвязывающие фрагменты и их использование для уменьшения объема новообразований
WO2009055823A3 (en) Method to predict responsiveness of breast cancer to polyaminetype chemotherapy
WO2009019370A3 (fr) Procede de dosage de l'apolipoproteine aii pour le diagnostic in vitro du cancer colorectal
WO2007120787A3 (en) Methods of treating, diagnosing or detecting cancers associated with liv-1 overexpression
WO2012138715A3 (en) Small molecule inhibitors of xbp1 splicing
ATE525484T1 (de) Slco1b3-genotyp